Teva Pharmaceutical Industries ADR (TEVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 09-2015 | 06-2015 | 03-2015 | 12-2014 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 1,597,000 | 1,099,000 | 983,000 | 444,000 | 3,042,000 |
| Depreciation Amortization | 1,308,000 | 973,000 | 658,000 | 335,000 | 1,508,000 |
| Income taxes - deferred | 237,000 | -97,000 | -404,000 | -190,000 | -226,000 |
| Accounts receivable | 763,000 | N/A | N/A | N/A | 710,000 |
| Other Working Capital | 967,000 | 703,000 | 1,166,000 | 557,000 | 290,000 |
| Other Operating Activity | 670,000 | 1,249,000 | 431,000 | 208,000 | -197,000 |
| Operating Cash Flow | $5,542,000 | $3,927,000 | $2,834,000 | $1,354,000 | $5,127,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -248,000 | -16,000 | 81,000 | -103,000 | -733,000 |
| Net Acquisitions | -3,309,000 | -3,304,000 | -3,261,000 | N/A | -363,000 |
| Purchase Of Investment | -2,003,000 | -1,926,000 | -1,935,000 | -118,000 | -324,000 |
| Other Investing Activity | -5,000 | -26,000 | -21,000 | 2,000 | -30,000 |
| Investing Cash Flow | $-5,565,000 | $-5,272,000 | $-5,136,000 | $-219,000 | $-1,450,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 29,000 | 1,548,000 | 2,414,000 | 17,000 | -385,000 |
| Debt Issued | 5,390,000 | 2,148,000 | 2,147,000 | 2,145,000 | N/A |
| Debt Repayment | -2,521,000 | -2,477,000 | -2,468,000 | -1,458,000 | -839,000 |
| Common Stock Issued | 3,679,000 | 339,000 | 258,000 | 166,000 | 514,000 |
| Common Stock Repurchased | -439,000 | -439,000 | -439,000 | -439,000 | -500,000 |
| Dividend Paid | -1,155,000 | -865,000 | -578,000 | -290,000 | -1,156,000 |
| Other Financing Activity | -178,000 | -164,000 | -154,000 | -48,000 | -9,000 |
| Financing Cash Flow | $4,805,000 | $90,000 | $1,180,000 | $93,000 | $-2,375,000 |
| Exchange Rate Effect | -62,000 | -43,000 | -36,000 | -58,000 | -114,000 |
| Beginning Cash Position | 2,226,000 | 2,226,000 | 2,226,000 | 2,226,000 | 1,038,000 |
| End Cash Position | 6,946,000 | 928,000 | 1,068,000 | 3,396,000 | 2,226,000 |
| Net Cash Flow | $4,720,000 | $-1,298,000 | $-1,158,000 | $1,170,000 | $1,188,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 5,542,000 | 3,927,000 | 2,834,000 | 1,354,000 | 5,127,000 |
| Capital Expenditure | -772,000 | -524,000 | -354,000 | -185,000 | -929,000 |
| Free Cash Flow | 4,770,000 | 3,403,000 | 2,480,000 | 1,169,000 | 4,198,000 |